Peri-operative Alemtuzumab (Campath-1H) and Plasmapheresis for High-PRA Positive Lymphocyte Crossmatch Heart Transplant: A Strategy to Shorten Left Ventricular Assist Device Support

Lick, Scott D.; Vaidya, Smita; Kollar, Andras; Boor, Paul J.; Vertrees, Roger A.

doi:10.1016/j.healun.2008.06.004

Cited by 18 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 In recent years, alemtuzumab (Campath-1H), a monoclonal antibody that binds to CD52, has been introduced in allosensitized cardiac patients with promising results. Lick et al 9 reported that alemtuzumab was effective, enabling transplant in sensitized patients.…”

Section: Discussionmentioning

confidence: 99%

Heart Transplant Recipient with History of Chagas Disease and Elevated Panel-Reactive Antibodies

Davalos-Krebs

2015

Prog Transpl

View full text Add to dashboard Cite

Chagas disease is caused by a protozoan named Trypanosoma cruzi transmitted to humans by reduviid bugs. Severe dilated cardiomyopathy from chronic T cruzi infection is the most common finding, leading to end-stage heart failure. Heart transplant is an effective treatment for Chagas heart disease. However, T cruzi reactivation is of great concern, predisposing patients to episodes of myocarditis and rejection. A 56-year-old woman with a history of Chagas disease and elevated calculated panel reactive antibodies (CPRAs) underwent induction therapy and desensitization strategies aimed at lowering CPRAs, as elevated CPRAs have been implicated in the development of antibody-mediated rejection and reduced allograft survival. Clinical phases and signs and symptoms of Chagas disease are briefly described in an attempt to promote awareness of the disease among clinicians. In addition, serology assays approved in the United States as well as recommendations of experts on Chagas disease to assess tissues and blood specimens from endemic areas are outlined. Ultimately, the importance of ongoing surveillance is emphasized, as the future of heart transplant recipients with Chagas disease is unpredictable and the presence or reactivation of the disease requires prompt attention in an effort to prevent graft failure and death.

show abstract

Section: Discussionmentioning

confidence: 99%

Heart Transplant Recipient with History of Chagas Disease and Elevated Panel-Reactive Antibodies

Davalos-Krebs

2015

Prog Transpl

View full text Add to dashboard Cite

show abstract

“…Few case reports have been published that detail limited success with alemtuzumab in isolated cases of OHT induction in children 37 and refractory rejection states. 38,39 In these reports, alemtuzumab has produced a beneficial effect on the detailed overwhelming rejection of these patients. [37][38][39] Conversely, no safety data have been presented in these populations.…”

Section: Anti-cd52 Strategymentioning

confidence: 96%

Induction Immunosuppression for Orthotopic Heart Transplantation: A Review

et al. 2009

View full text Add to dashboard Cite

show abstract

“…A small, single-center series recently published detailed the use of alemtuzumab in patients transplanted with positive retrospective crossmatches [60 ] with promising efficacy. Given the modest efficacy reported to most contemporary desensitization strategies, this approach may be particularly appealing pending confirmation with long-term follow-up.…”

Section: Inductionmentioning

confidence: 99%